undamentalytics Newsletter
Sign in

Genelux Corp income statement

In fiscal 2025, Genelux Corp reported revenue of $8,000, up 0.0% on the year before, operating income of −$33.2m (a -415175.0% margin) and net income of −$32.1m, or −$0.86 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue11000
Research and development9131920
General and administrative5121313
Operating income−3−24−32−33
Interest expense—0——
Income tax1———
Net income−5−28−30−32
Diluted EPS−$0.57−$1.16−$0.95−$0.86
Diluted shares (average)9m24m31m37m
EBITDA−2−24−31−33

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CELZ vs GNLXGNLX vs LYELAIM vs GNLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Genelux Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Genelux Corp.